• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas.人乳腺癌中TP53错义突变免疫组化检测的合理手动及自动评分阈值
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):398-404. doi: 10.1097/PAI.0000000000000207.
2
A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.通过免疫组织化学测定的p53蓄积与TP53突变作为乳腺癌患者肿瘤预后变量的比较。
Acta Oncol. 2008;47(4):600-7. doi: 10.1080/02841860802047411.
3
Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.人类乳腺癌中突变型p53的积累并非内在特性,也不依赖于结构或功能破坏,而是受外源性应激和受体状态调控。
J Pathol. 2014 Jul;233(3):238-46. doi: 10.1002/path.4356. Epub 2014 May 21.
4
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.BRCA1相关乳腺癌中蛋白质截短型TP53突变的高发生率。
Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.
5
P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach.乳腺癌中的P53:使用半定量方法分析突变存在与免疫组化表达之间的关联
Pathol Res Pract. 1998;194(12):815-9. doi: 10.1016/s0344-0338(98)80083-6.
6
Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of Missense Mutation in Prostate Cancer.用于检测前列腺癌错义突变的p53免疫组化分析、分析前及临床验证
Clin Cancer Res. 2017 Aug 15;23(16):4693-4703. doi: 10.1158/1078-0432.CCR-17-0257. Epub 2017 Apr 26.
7
Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.低分期散发性卵巢癌的临床病理分析:再评价。
Am J Surg Pathol. 2013 Mar;37(3):356-67. doi: 10.1097/PAS.0b013e318272ff19.
8
p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.腔面型乳腺癌中 p53 的表达与 TP53 突变和原发性内分泌耐药相关。
Mod Pathol. 2023 Apr;36(4):100100. doi: 10.1016/j.modpat.2023.100100. Epub 2023 Jan 11.
9
Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.通过p53和MDM2免疫组织化学鉴别人类肿瘤中功能性和非功能性p53
J Pathol. 2005 Nov;207(3):251-9. doi: 10.1002/path.1838.
10
p53 protein expression patterns associated with TP53 mutations in breast carcinoma.乳腺癌中与 TP53 突变相关的 p53 蛋白表达模式。
Breast Cancer Res Treat. 2024 Aug;207(1):213-222. doi: 10.1007/s10549-024-07357-z. Epub 2024 Jun 20.

引用本文的文献

1
Prognostic Importance of PTEN and P53 in Aggressive Luminal A Subtype Breast Cancers.PTEN和P53在侵袭性管腔A型乳腺癌中的预后重要性
Eur J Breast Health. 2025 Jun 20;21(3):246-254. doi: 10.4274/ejbh.galenos.2025.2025-2-12. Epub 2025 May 20.
2
Poor Endometrial Proliferation After Clomiphene is Associated With Altered Estrogen Action.氯米酚治疗后子宫内膜增殖不良与雌激素作用改变有关。
J Clin Endocrinol Metab. 2021 Aug 18;106(9):2547-2565. doi: 10.1210/clinem/dgab381.
3
Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas.RAS 突变和 P53 表达在皮肤鳞状细胞癌中的预后意义。
Genes (Basel). 2020 Jul 6;11(7):751. doi: 10.3390/genes11070751.
4
Non-disruptive mutation in DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma.DNA结合域中的非破坏性突变是食管鳞状细胞癌的一个有利因素。
Ann Transl Med. 2020 Mar;8(6):316. doi: 10.21037/atm.2020.02.142.
5
Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas.浸润性导管癌和小叶癌女性患者在种族、分子及肿瘤特征方面的差异。
Cancer Causes Control. 2019 Jan;30(1):31-39. doi: 10.1007/s10552-018-1121-1. Epub 2019 Jan 8.
6
Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report.通过对纯细胞群体的数字分选鉴定原发性和转移性食管腺癌的基因组谱:病例报告结果。
BMC Cancer. 2018 Sep 12;18(1):889. doi: 10.1186/s12885-018-4789-4.
7
TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases.浸润性乳腺癌病例中的TP53蛋白水平、基于RNA的通路评估及种族情况。
NPJ Breast Cancer. 2018 Jun 25;4:13. doi: 10.1038/s41523-018-0067-5. eCollection 2018.
8
Prognostic significance of CD117 expression and missense mutations in triple-negative breast cancer.CD117表达及错义突变在三阴性乳腺癌中的预后意义
Oncol Lett. 2018 May;15(5):6161-6170. doi: 10.3892/ol.2018.8104. Epub 2018 Feb 22.

本文引用的文献

1
Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.老年早期乳腺癌患者应用来曲唑一线治疗的临床反应:p53 作为生物标志物的可能作用。
Int J Surg. 2014;12(8):821-6. doi: 10.1016/j.ijsu.2014.06.009. Epub 2014 Jul 8.
2
Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer.p53 过表达的定义及其与腔面/HER2 阴性乳腺癌临床病理特征的关系。
Anticancer Res. 2013 Sep;33(9):3891-7.
3
Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.p53 功能获得性突变在高级别浆液性卵巢癌中的临床意义。
PLoS One. 2013 Aug 13;8(8):e72609. doi: 10.1371/journal.pone.0072609. eCollection 2013.
4
Comprehensive molecular portraits of human breast tumours.人类乳腺肿瘤的全面分子特征图谱。
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
5
The rebel angel: mutant p53 as the driving oncogene in breast cancer.叛逆天使:乳腺癌中的突变型 p53 作为驱动致癌基因。
Carcinogenesis. 2012 Nov;33(11):2007-17. doi: 10.1093/carcin/bgs232. Epub 2012 Jul 20.
6
Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis.TP53 状态预测乳腺癌新辅助化疗反应的价值:一项荟萃分析。
PLoS One. 2012;7(6):e39655. doi: 10.1371/journal.pone.0039655. Epub 2012 Jun 29.
7
TP53 status and response to treatment in breast cancers.乳腺癌中TP53状态与治疗反应
J Biomed Biotechnol. 2011;2011:284584. doi: 10.1155/2011/284584. Epub 2011 May 9.
8
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.p53 的免疫组化染色模式可作为卵巢癌中 TP53 突变的替代标志物:免疫组化和核苷酸测序分析。
Mod Pathol. 2011 Sep;24(9):1248-53. doi: 10.1038/modpathol.2011.85. Epub 2011 May 6.
9
High-grade and low-grade pelvic serous neoplasms demonstrate differential p53 immunoreactivity in peritoneal washings.
Acta Cytol. 2011;55(1):79-84. doi: 10.1159/000320862. Epub 2010 Nov 26.
10
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.COSMIC:在癌症体细胞突变目录中挖掘完整的癌症基因组。
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50. doi: 10.1093/nar/gkq929. Epub 2010 Oct 15.

人乳腺癌中TP53错义突变免疫组化检测的合理手动及自动评分阈值

Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas.

作者信息

Taylor Nicholas J, Nikolaishvili-Feinberg Nana, Midkiff Bentley R, Conway Kathleen, Millikan Robert C, Geradts Joseph

机构信息

*Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL †Translational Pathology Laboratory, School of Medicine ‡Lineberger Comprehensive Cancer Center §Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill ∥Department of Pathology, Duke University School of Medicine, Durham, NC.

出版信息

Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):398-404. doi: 10.1097/PAI.0000000000000207.

DOI:10.1097/PAI.0000000000000207
PMID:26200835
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4716889/
Abstract

Missense mutations in TP53 are common in human breast cancer, have been associated with worse prognosis, and may predict therapy effect. TP53 missense mutations are associated with aberrant accumulation of p53 protein in tumor cell nuclei. Previous studies have used relatively arbitrary cutoffs to characterize breast tumors as positive for p53 staining by immunohistochemical assays. This study aimed to objectively determine optimal thresholds for p53 positivity by manual and automated scoring methods using whole tissue sections from the Carolina Breast Cancer Study. p53-immunostained slides were available for 564 breast tumors previously assayed for TP53 mutations. Average nuclear p53 staining intensity was manually scored as negative, borderline, weak, moderate, or strong and percentage of positive tumor cells was estimated. Automated p53 signal intensity was measured using the Aperio nuclear v9 algorithm combined with the Genie histology pattern recognition tool and tuned to achieve optimal nuclear segmentation. Receiver operating characteristic curve analysis was performed to determine optimal cutoffs for average staining intensity and percent cells positive to distinguish between tumors with and without a missense mutation. Receiver operating characteristic curve analysis demonstrated a threshold of moderate average nuclear staining intensity as a good surrogate for TP53 missense mutations in both manual (area under the curve=0.87) and automated (area under the curve=0.84) scoring systems. Both manual and automated immunohistochemical scoring methods predicted missense mutations in breast carcinomas with high accuracy. Validation of the automated intensity scoring threshold suggests a role for such algorithms in detecting TP53 missense mutations in high throughput studies.

摘要

TP53基因的错义突变在人类乳腺癌中很常见,与较差的预后相关,并且可能预测治疗效果。TP53错义突变与肿瘤细胞核中p53蛋白的异常积累有关。以往的研究使用相对任意的阈值,通过免疫组织化学检测将乳腺肿瘤表征为p53染色阳性。本研究旨在通过手动和自动评分方法,使用卡罗来纳乳腺癌研究中的全组织切片,客观地确定p53阳性的最佳阈值。有564例先前检测过TP53突变的乳腺肿瘤的p53免疫染色玻片。手动将细胞核p53染色强度评为阴性、临界、弱、中度或强,并估计阳性肿瘤细胞的百分比。使用Aperio细胞核v9算法结合Genie组织学模式识别工具测量自动p53信号强度,并进行调整以实现最佳的细胞核分割。进行受试者工作特征曲线分析,以确定平均染色强度和阳性细胞百分比的最佳阈值,以区分有错义突变和无错义突变的肿瘤。受试者工作特征曲线分析表明,在手动(曲线下面积=0.87)和自动(曲线下面积=0.84)评分系统中,中等平均细胞核染色强度阈值是TP53错义突变的良好替代指标。手动和自动免疫组织化学评分方法都能高精度地预测乳腺癌中的错义突变。自动强度评分阈值的验证表明,此类算法在高通量研究中检测TP53错义突变方面具有作用。